James Ritchie

James is currently the Drug Development Scientist at Cancer Research UK’s Centre for Drug Development (CRUK CDD) and has been working in the field of oncology drug discovery and development since 2001. Prior this, he held several positions at TopoTarget A/S (formerly Prolifix Ltd), mainly working on the belinostat (Beleodaq®) programme, which became a registered medicine in 2014. As part of the CRUK CDD he is focussed on the translational and early clinical development of new anti-cancer agents covering everything from small molecules to biologicals and immune therapies.